Newborn Blood Spot Test, in Visit Clinic

A newborn blood spot (heel-prick) screens babies for a panel of rare but serious conditions early, including metabolic disorders (phenylketonuria, medium‑chain acyl‑CoA dehydrogenase deficiency), endocrine problems (congenital hypothyroidism), cystic fibrosis, and haemoglobinopathies (sickle cell disease and thalassaemia). The exact panel varies by region. Early detection enables prompt treatment to prevent developmental delay, organ damage or life‑threatening crises.

The newborn blood test (heel‑prick) screens for a panel of rare but serious conditions that are treatable if found early. Typical targets include metabolic disorders (phenylketonuria, MCADD), endocrine problems (congenital hypothyroidism), cystic fibrosis, and haemoglobin disorders (sickle cell/thalassaemia). Exact conditions screened vary by region. Screening is usually done around day five of life.

Newborn blood spot screening (heel-prick) is usually performed when the baby is about 5 days old (ideally between days 5–8). It should be done after at least 48 hours of feeding for accurate metabolic results. If the baby is discharged earlier, a sample may be taken before discharge and repeated at day 5–8; preterm, transfused, or unwell infants may need additional testing.

A spot blood test uses a small capillary sample (finger‑prick or heel) for quick, point‑of‑care checks. It can measure blood glucose, hemoglobin, HbA1c, some lipids and inflammatory markers (e.g., CRP) or rapid infectious screens. Results give immediate screening or monitoring information but are less comprehensive than full laboratory venous tests; abnormal values usually need confirmatory lab testing.

The newborn blood spot (heel‑prick) is done on day 5 because metabolic and endocrine markers need time to appear after birth and feeding; testing too early can miss conditions. Day‑5 timing maximizes test sensitivity for disorders like PKU, congenital hypothyroidism and haemoglobinopathies, enabling prompt treatment to prevent harm while allowing reliable results and practical follow‑up with primary care.

Parents may sometimes refuse newborn screening, but rules differ by country or state: some programs are mandatory, others allow opt-out for religious or personal reasons, often requiring a signed refusal. Refusal risks missing early detection and timely treatment for serious conditions. Parents should discuss benefits, risks, and legal requirements with their newborn’s healthcare provider before deciding.